Nevro Q2 2021 Earnings Report
Key Takeaways
Nevro Corp. reported an 81% increase in worldwide revenue compared to the prior year, reaching $102.3 million. The company also announced FDA approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy (PDN).
Worldwide revenue increased by 81% compared to the prior year and 9% compared to 2019, reaching $102.3 million.
Net loss from operations improved by 55% compared to the prior year, with a net loss of $15.8 million.
FDA approved 10 kHz High Frequency Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy (PDN).
Gross margin increased to 68.4% compared to 62.5% in the prior year period.
Nevro
Nevro
Forward Guidance
Nevro expects third quarter worldwide revenue of approximately $90 million to $93 million and non-GAAP adjusted EBITDA to be approximately negative $10 million to negative $12 million.